News

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) can radiographically mimic multiple sclerosis (MS) and aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Central vein sign (CVS) prevalence has not yet been well-established in MOGAD. The objective of this study is to characterize the magnetic resonance imaging (MRI) appearance and CVS prevalence of MOGAD patients in comparison to matched cohorts of MS and AQP4+ NMOSD.

Join us virtually on June 5 for our annual Illumination Gala to learn more about how the Cancer Frontier Fund is supporting breakthrough research at Siteman Cancer Center.

Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune demyelinating disease.
Its pathogenesis involves humoral and cellular immunity, with production of pro- and anti-inflammatory
cytokines by T cells.

To identify and characterize myeloid cell populations within the CSF of patients with MS and anti-myelin oligodendrocyte glycoprotein (MOG) disorder by high-resolution single-cell gene expression analysis.

Development of long-term immunologic memory relies upon humoral and cellular immune responses.
Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the
impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these
studies have important implications for people with multiple sclerosis who require vaccination and are using
disease-modifying therapies.

Multiple sclerosis (MS) is a heterogeneous disease. With several disease modifying treatments of different
mechanisms of action in use now and in development, it is important to identify reliable biomarkers
to identify those higher risk MS patients in whom stronger but riskier treatments might be used, as well as
to identify those for whom safer treatments of lower efficacy would be sufficient.

The Foundation is very pleased to welcome six new board members in 2021. You can read more about the first three here.